Samantha Tabone is General Partner at XEIA Venture Partners, an early-stage venture capital firm investing at the intersection of frontier life sciences, deep technology, and medtech. With a focus on the “Human 3” thesis, she backs founders developing transformative solutions in neuroscience, psychiatry, and neurodegenerative disease, as well as enabling platforms that redefine human performance and longevity.
Her career bridges science, investment, and entrepreneurship. Trained in chemistry and CNS pharmacology, Samantha began her journey working across biotech ecosystems where she honed her ability to evaluate translational science and company-building opportunities. Prior to launching XEIA, she advised and collaborated with biotech founders, gaining deep expertise in identifying high-potential approaches to new drug discovery such as epigenetic modulation, RNA-based modalities, and new target identification for neurodegenerative disease.
At XEIA, she combines scientific rigor with operational discipline, leading investments, shaping portfolio strategy, and engaging closely with limited partners. Her role extends beyond capital allocation: she is a community builder, having launched initiatives such as the San Francisco Biotech Run Club and the Human 3 Podcast, platforms designed to connect scientists, entrepreneurs, and investors around the future of human health.
Samantha’s work reflects her belief that venture capital should be both catalyst and collaborator—accelerating groundbreaking science while supporting visionary founders. XEIA Venture Partners has invested in 26 companies and is now allocating our of their second fund.